Latest Videos

Latest News

Bristol Myers Squibb to Access Cellares' Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal

Bristol Myers Squibb to Access Cellares' Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal

April 24th 2024

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb.

Charles River to Provide pDNA Manufacturing Services in Two Deals

Charles River to Provide pDNA Manufacturing Services in Two Deals

April 11th 2024

Charles River has entered into separate agreements with Axovia Therapeutics and Ship of Theseus to offer plasmid DNA manufacturing services for a gene therapy and a lead candidate program, respectively.

Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy

Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy

April 5th 2024

Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.

Genmab Expands ADC Pipeline with $1.8 Billion Acquisition of ProfoundBio

Genmab Expands ADC Pipeline with $1.8 Billion Acquisition of ProfoundBio

April 4th 2024

Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.

Dr. Reddy’s Partners with Sanofi Healthcare India to Distribute Vaccines

Dr. Reddy’s Partners with Sanofi Healthcare India to Distribute Vaccines

March 29th 2024

Dr. Reddy’s has gained exclusive rights to promote and distribute Sanofi’s vaccines in India.

Roche Sells Large-Scale Biologics Manufacturing Site in US to Lonza for $1.2 Billion

Roche Sells Large-Scale Biologics Manufacturing Site in US to Lonza for $1.2 Billion

March 26th 2024

The Vacaville, Calif., site acquisition gives Lonza one of the largest biologics manufacturing sites for mammalian cell-based therapies worldwide.

Ricoh and ERS Genomics Enter License Agreement for CRISPR/Cas9 Technology

Ricoh and ERS Genomics Enter License Agreement for CRISPR/Cas9 Technology

March 19th 2024

Ricoh aims to create novel disease models for R&D using ERS Genomics’ CRISPR/Cas9 genome editing technology.

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

March 16th 2024

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

March 14th 2024

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

Bormioli Pharma’s Business Expands in United States

Bormioli Pharma’s Business Expands in United States

March 12th 2024

The European company has seen its business increase by 47% in North America.